
    
      This is a multi-center phase II randomized controlled study to assess the safety and efficacy
      of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small
      cell lung cancer that achieve stable disease after 8 weeks routine therapy by PFS, as well as
      OS and DCR. The adverse events and adverse reaction are evaluated as well.
    
  